Last reviewed · How we verify
NA picosulfate magnesium citrate
NA picosulfate magnesium citrate is a Small molecule drug developed by Norgine. It is currently in Phase 2 development.
At a glance
| Generic name | NA picosulfate magnesium citrate |
|---|---|
| Sponsor | Norgine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Tolerance and Safety of Split Dose Bowel Preparation for Colonoscopy: 4L Polyethylene Glycol (PEG) Versus 1L Polyethylene Glycol Plus Sodium Picosulfate-magnesium Citrate (SPMC) (PHASE4)
- MOVIPREP® Versus PICOLAX® Pilot Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NA picosulfate magnesium citrate CI brief — competitive landscape report
- NA picosulfate magnesium citrate updates RSS · CI watch RSS
- Norgine portfolio CI
Frequently asked questions about NA picosulfate magnesium citrate
What is NA picosulfate magnesium citrate?
NA picosulfate magnesium citrate is a Small molecule drug developed by Norgine.
Who makes NA picosulfate magnesium citrate?
NA picosulfate magnesium citrate is developed by Norgine (see full Norgine pipeline at /company/norgine).
What development phase is NA picosulfate magnesium citrate in?
NA picosulfate magnesium citrate is in Phase 2.
Related
- Manufacturer: Norgine — full pipeline
- Compare: NA picosulfate magnesium citrate vs similar drugs
- Pricing: NA picosulfate magnesium citrate cost, discount & access